OGTT

ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes

Retrieved on: 
Wednesday, January 31, 2024
ROS, Inflammation, Uric acid, Insulin resistance, Research, Obesity, Cardiovascular disease, Glucose, Type, OGTT, Hypertension, ASC, Therapy, Journal of Translational Medicine, Risk, Journal, Type 2 diabetes, Serum, Translational medicine, NLRP3, Oxidative stress, Inflammasome, Pharmaceutical industry

ZyVersa is developing Inflammasome ASC Inhibitor IC 100 which inhibits NLRP3 and other types of inflammasomes and their associated ASC specks to attenuate initiation and perpetuation of damaging inflammation.

Key Points: 
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100 which inhibits NLRP3 and other types of inflammasomes and their associated ASC specks to attenuate initiation and perpetuation of damaging inflammation.
  • In the paper titled, “Altered insulin secretion dynamics relate to oxidative stress and inflammasome activation in children with obesity and insulin resistance,” the authors conducted a case-controlled study of 132 children who were either lean or obese.
  • The authors concluded, “It is insulin response to an OGTT that identifies children with obesity suffering oxidative stress, and inflammasome activation more specifically.
  • “The research published in the Journal of Translational Medicine points to a significant role for inflammasome-mediated inflammation and oxidative stress in development of metabolic complications in obese children.

Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at ObesityWeek®

Retrieved on: 
Sunday, October 15, 2023
Type 2 diabetes, RA, Insulin, Pharmacokinetics, Doctor of Philosophy, Obesity, Insulin resistance, T2D, Weight loss, Central nervous system, MD, Physician, Risk, Therapy, OGTT, Diabetes, GIP, Safety, MOA, Overweight, Glucose, DSM-IV codes, Patient, Poster, Pharmaceutical industry, Medical device, Medical imaging, Philosopher's stone

DALLAS, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics Inc. (Carmot), a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people with metabolic diseases, today announced positive results from the following studies: a study of CT-388 to evaluate the safety/tolerability, efficacy, and pharmacokinetics of CT-388 in people with overweight/obesity without type 2 diabetes (T2D), a study of CT-868 assessing the efficacy and safety of CT-868 in overweight/obese patients with T2D, and a preclinical mechanism of action (MOA) study to investigate the impact of a unimolecular dual biased GLP-1/GIP receptor agonist (RA) in regulating weight loss and food intake. The results are summarized in three poster presentations taking place at ObesityWeek® October 14-17, 2023.

Key Points: 
  • An oral glucose tolerance test was performed on Day -1 (baseline) and Day 23 (post the 4th dose).
  • CT-388 dosed at 5/8/12/12 mg produced 8.4% weight loss (~17 lbs) accompanied by a decrease in waist and hip circumference.
  • Overall, these data support further clinical evaluation of CT-388, with higher doses while maintaining and exploring simpler titration schemes, for the treatment of obesity, T2D and other weight-related comorbidities.
  • Carmot has designed the ongoing Phase 1/2 CT-388 clinical trial to evaluate a higher starting dose, a higher maximum dose and simpler titration schemes.

Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights

Retrieved on: 
Monday, July 31, 2023
Momentum, CLL, PDAC, KRAS, Insulin, Food, American Diabetes Association, CRC, Diabetes, Investment, Chronic lymphocytic leukemia, ALL, Week, Menin, DLBCL, Multiple myeloma, NPM1, CD135, Bone marrow, OGTT, Type 2 diabetes, Mutation, G&A, NSCLC, B-cell lymphoma, QT interval, NUP98, AML, Hypoglycemia, HIV disease progression rates, Patient, DSM-IV codes, C-peptide, Administration, Cancer, MM, FLT3, CRS, Research and development, Commonwealth Fusion Systems, Research, R, ADA, IND, Disease, Pharmaceutical industry, Silviculture, Fine chemical, Vaccine, Medical imaging, Cryptocurrency, Glycated hemoglobin, Osteopathic medicine in Canada

Our goal at Biomea is to develop a treatment that can halt or reverse disease progression in patients with type 1 and type 2 diabetes.

Key Points: 
  • Our goal at Biomea is to develop a treatment that can halt or reverse disease progression in patients with type 1 and type 2 diabetes.
  • We look forward to continuing to evaluate BMF-219’s proposed mechanism of action and its potential therapeutic impact as this study progresses.
  • BMF-500 is an investigational oral covalent inhibitor of FLT3, designed and developed in-house, and the second investigational compound discovered by Biomea’s FUSION™ System.
  • G&A expenses were $11.4 million for the six months ended June 30, 2023 compared to $9.9 million for the same period in 2022.

ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the ASMBS 2023 Annual Meeting

Retrieved on: 
Wednesday, June 28, 2023
Insulin, Diet, Weight loss, Pancreas, OGTT, Diabetes, T2DM, Organization, Metabolism, Alloxan, Blood, Annual general meeting, Liver, ASMBS, Research, Pig, Society, NIH, Bariatric surgery, AU, Pharmaceutical industry, AUC, Zucker

“Type 2 Diabetes Mellitus (T2DM) remains challenging to effectively treat, despite medication, surgery and diet,” stated Jonathan Waataja, Ph.D. Director of Research at ReShape Lifesciences.

Key Points: 
  • “Type 2 Diabetes Mellitus (T2DM) remains challenging to effectively treat, despite medication, surgery and diet,” stated Jonathan Waataja, Ph.D. Director of Research at ReShape Lifesciences.
  • “ReShape’s DBSN™ device selectively modulates vagal block and stimulation to the liver and pancreas to manage blood glucose.
  • Increased glycemic control has been demonstrated in a Zucker rat model of T2DM as well as in an alloxan treated swine model of T2DM.
  • There was an apparent, but non-significant, increase in baseline insulin following stimulation and block experiments (pre-experiments =10.7±2.6 µIU/mL, post-experiments=15.4±2.9 µIU/mL, p=0.28).

Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort 3 D

Retrieved on: 
Saturday, June 24, 2023
Glycated hemoglobin, Food, Diabetes, American Board of Obstetrics and Gynecology, Cohort, Week, Clinical trial, Pancreas, OGTT, Type 2 diabetes, QD, Regeneration, Patient, DSM-IV codes, C-peptide, Cancer, MAD, Health, Phase, Safety, Osteopathic medicine in Canada, Disease, Pharmaceutical industry, Silviculture, T2D

These landmark findings support the potential disease-modifying impact of BMF-219,” said Thomas Butler, Biomea Fusion’s Chief Executive Officer and Chairman of the Board.

Key Points: 
  • These landmark findings support the potential disease-modifying impact of BMF-219,” said Thomas Butler, Biomea Fusion’s Chief Executive Officer and Chairman of the Board.
  • These historic data support our goal for BMF-219 to become the first disease-modifying treatment for patients with diabetes.
  • Phase II consists of multiple ascending dose (MAD) cohorts and includes adult patients with type 2 diabetes uncontrolled by current therapies.
  • Additional information about the Phase I/II clinical trial of BMF-219 in type 2 diabetes can be found at ClinicalTrials.gov using the identifier NCT05731544.

New Study Shows 1 in 5 “Healthy” Individuals Actually Have the Metabolism of a Prediabetic

Retrieved on: 
Wednesday, May 24, 2023
Men, Research, Other Health, General Health, Consumer, Fitness & Nutrition, Science, Other Consumer, Biotechnology, Women, Health, Diabetes, Other Science, CGM, Faculty, Type 2 diabetes, American Diabetes Association, Mathematics, Glucose, McMaster Faculty of Science, OGTT, Mayo Clinic Proceedings, Risk, IGH, Digital health, Patient, Ontario Tech University, Diagnosis, Aycart del Fossat, Himawari (satellites), BMI, Prediabetes, Glycated hemoglobin, Medical device, Dietary supplement, Pharmaceutical industry, Mitacs

When they applied their patented mathematical method to data obtained from continuous glucose monitors (CGMs), scientists found about one in five study participants, considered healthy by medical standards, actually had glucose metabolism similar to those with prediabetes.

Key Points: 
  • When they applied their patented mathematical method to data obtained from continuous glucose monitors (CGMs), scientists found about one in five study participants, considered healthy by medical standards, actually had glucose metabolism similar to those with prediabetes.
  • Participants were diagnosed diabetic, pre-diabetic, or healthy, according to guidelines outlined by the American Diabetes Association.
  • After applying the mathematical model, patients were then re-classified into two groups based on their glucose homeostasis parameters: effective or impaired.
  • About 34 million people have diabetes in the U.S. and one in three Americans have prediabetes or diabetes.

Aphaia Pharma Announces Dosing of First Patient in its Phase 2 Trial Evaluating its Lead Candidate APH-012 for Prediabetes

Retrieved on: 
Tuesday, April 25, 2023
Exercise, Aphaea, Medicine, Obesity, Diet, Diabetes, OGTT, Blood, Metabolism, DSM-IV codes, Patient, SAN, EudraCT, Prediabetes, Safety, Pharmaceutical industry

“We are pleased to continue to evaluate APH-012 in additional indications beyond obesity in the clinic since we believe in the potential of our unique approach to help treat multiple metabolic diseases,” said Kai Deusch, M.D.

Key Points: 
  • “We are pleased to continue to evaluate APH-012 in additional indications beyond obesity in the clinic since we believe in the potential of our unique approach to help treat multiple metabolic diseases,” said Kai Deusch, M.D.
  • Ph.D., Chief Business & Medical Officer of Aphaia Pharma.
  • Patients will be randomized to receive a once daily dose of either APH-012 or APH-012P, a matching placebo, for six weeks.
  • The primary endpoint of the trial is APH-012’s ability to improve glucose tolerance in individuals with a pathological oral glucose tolerance test (OGTT) after 6 weeks of administration.

Eating Almonds Before Meals Improved Blood Sugar Levels in Some People with Prediabetes

Retrieved on: 
Wednesday, March 22, 2023
Breakfast, Exercise, Hyperglycemia, Insulin, Food, Diet, Zinc, Shoulder, Diabetes, Prevalence, Public, Magnesium, Glucose, Glucagon, DV, OGTT, Lipid, Vitamin E, C-reactive protein, Nutrient, Meal, Head, Research, Medicine, Almond, Prediabetes, Hormone, Human, A1C, Inborn errors of metabolism, Waist, Blood, National Diabetes Education Program, Professor, CGMS, Risk, C-peptide, Lunch, Overweight, Clutch (eggs), PPHG, Body mass index, Hunger, Potassium, Birth control, Dietary supplement, Pharmaceutical industry, Medical device, Obesity, Proinsulin, Endocrinology

MODESTO, Calif., March 22, 2023 /PRNewswire/ -- Two new research studies1-2 with almonds, one conducted over three days and the other over three months, demonstrated benefits to blood sugar control for Asian Indians with prediabetes and overweight/obesity – and the three-month almond intervention broke new ground, reversing prediabetes, or glucose intolerance, to normal blood sugar levels in nearly one quarter (23.3%) of the people studied.

Key Points: 
  • The findings complement the breadth of research on different populations on how almonds support healthy blood sugar as part of a balanced diet.
  • "Results from our studies indicate almonds might be a key differentiator in helping regulate blood glucose levels as part of a dietary strategy.
  • Eating 20 g of almonds 30 minutes before an oral glucose load showed a significant decrease in blood sugar and hormones.
  • These substantial metabolic improvements led to nearly one-fourth (23.3%) of the prediabetes study participants returning to normal blood glucose regulation.

OrsoBio Announces First Patient Dosed in Phase 2 Clinical Trial of the ACC2 Inhibitor TLC-3595, a Potential Treatment for Type 2 Diabetes

Retrieved on: 
Monday, March 20, 2023
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Glycated hemoglobin, Insulin resistance, Yale School of Medicine, FRCP, Obesity, NASH, Glucose, Cardiovascular disease, OGTT, Cancer, Type 2 diabetes, Lipid, Liver, Yale school, Biomarker, Doctor of Philosophy, MACE, MACP, FAO, DSM-IV codes, Kidney, Acetyl-CoA, MRS, MD, Patient, LDL, Overweight, Fatty liver disease, Poster, Prediabetes, Abstract, Safety, Pharmaceutical industry, Medicine

OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced that the first patient has been dosed in a Phase 2a clinical trial evaluating TLC-3595, a selective inhibitor of acetyl-CoA carboxylase 2 (ACC2).

Key Points: 
  • OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced that the first patient has been dosed in a Phase 2a clinical trial evaluating TLC-3595, a selective inhibitor of acetyl-CoA carboxylase 2 (ACC2).
  • The trial aims to demonstrate the safety and insulin-sensitizing effects of TLC-3595 in patients with insulin resistance, including those with type 2 diabetes on approved glucose-lowering therapies.
  • Proof-of-concept data supporting the safety and efficacy of TLC-3595 will be available by the end of 2023.
  • The study will enroll 50 overweight or obese subjects with insulin resistance, including type 2 diabetes treated with glucose-lowering therapies.

Aphaia Pharma to Participate in the LSX Leaders Inv€$tival Showcase

Retrieved on: 
Monday, November 7, 2022
Obesity, GLOBE, Conference, LSX, Prediabetes, Jefferies, GI, Partnership, OGTT, Pharmaceutical industry, Video game

Members of the management team will present a corporate overview at the LSX Inv$tival Showcase and will be available for one-on-one meetings during the LSX Inv$tival Showcase and the Jefferies conference.

Key Points: 
  • Members of the management team will present a corporate overview at the LSX Inv$tival Showcase and will be available for one-on-one meetings during the LSX Inv$tival Showcase and the Jefferies conference.
  • The Inv$tival Showcase is an LSX Leaders event in partnership with the global investment bank Jefferies and the annual European Lifestars Awards, with the showcase serving as the pre-day to Jefferies London Healthcare Conference.
  • Aphaias lead candidate, APH-012, a glucose formulation, has been shown to safely restore endogenous hormone release in individuals with obesity.
  • The versatile design of Aphaias technology platform provides an opportunity for the development of treatments for multiple disease patterns.